News | April 01, 2015

iCAD Presents Clinical Trial Data on Xoft Axxent Electronic Brachytherapy System

Results suggest isotope-free radiation treatment effective for non-melanoma skin cancer

iCAD, Xoft Axxent, brachytherapy, studies, non-melanoma skin cancer

April 1, 2015 — iCAD Inc. researchers presented three e-posters highlighting results of up to four years of follow-up with the Xoft Axxent electronic brachytherapy (eBx) system at The American Academy of Dermatology 73rd Annual Meeting in San Francisco. The Xoft System is used in the treatment of non-melanoma skin cancer (NMSC).

The E-posters that were presented at the meeting included:

  • “Electronic Brachytherapy for Non-Melanomatous Skin Cancer: Report of First 565 Lesions,” presented by Stephen Doggett, M.D., Aegis Oncology LLC
     
  • “Electronic Brachytherapy for the Treatment of Non-Melanoma Skin Cancer: Results up to 4 Years,” presented by Ajay Bhatnagar, M.D., MBA, 21st Century Oncology of Arizona
  • “Initial Experience of Electronic Brachytherapy for the Treatment of 508 Non-melanoma Skin Cancer (NMSC) Lesions in 305 Patients,” presented by Robert Strimling, M.D., FAAD and Camtu Lee Jones
     

Study results suggest that electronic brachytherapy is an effective treatment for patients with non-melanoma skin cancer, with few recurrences or side effects and excellent cosmetic results,” said Bhatnagar. “The studies support the use of the Xoft System for patients with non-melanoma skin cancer who are not candidates for surgical excision or traditional radiation therapy.”

At the meeting, iCAD also showcased its new comprehensive solution for clinical practices interested in implementing a skin electronic brachytherapy program. Comprised of the medical device, software, management services and support, Xoft Skin eBx offers a scalable and modular program that enables radiation oncology supervision with the necessary components to successfully incorporate a skin eBx program into any dermatology practice.

The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment.

For more information: www.icadmed.com

Related Content

Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Machine Learning Uncovers New Insights Into Human Brain Through fMRI
News | Neuro Imaging | January 11, 2019
An interdisciplinary research team led by scientists from the National University of Singapore (NUS) has successfully...
Mobile App Data Collection Shows Promise for Population Health Surveys
News | Population Health | January 10, 2019
Mobile app data collection can bring access to more potential clinical study participants, reduce clinical study...
Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Magnetic Resonance Imaging (MRI) | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Artificial Intelligence Pinpoints Nine Different Abnormalities in Head Scans

A brain scan (left) showing an intraparenchymal hemorrhage in left frontal region and a scan (right) of a subarachnoid hemorrhage in the left parietal region. Both conditions were accurately detected by the Qure.ai tool. Image courtesy of Nature Medicine.

News | Artificial Intelligence | January 07, 2019
The rise in the use of computed tomography (CT) scans in U.S. emergency rooms has been a well-documented trend1 in...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...